CAN FITE (Israel) Valuation

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 35px;;'>CAN</div>
CAN FITE BIOPHARMA prevailing Real Value cannot be determined due to lack of data. The current price of CAN FITE BIOPHARMA is 0.0. Based on Macroaxis valuation methodology, the entity cannot be evaluated at this time. This module approximates value of CAN FITE BIOPHARMA from examining the entity fundamentals such as Operating Margin of (158.79) , Price to Earning of (337.46)  and Profit Margin of (191.63)  as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since in the future assets prices and their ongoing real values will blend.
Horizon     30 Days    Login   to change
CAN FITE BIOPHARMA is rated second in price to book category among related companies. It is rated second in price to sales category among related companies fabricating about  0.02  of Price to Sales per Price to Book. The ratio of Price to Book to Price to Sales for CAN FITE BIOPHARMA is roughly  41.08 
Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also Trending Equities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Company logos by clearbit